BioLert

Company Overview

Snapshot

Founded in January 2010, BioLert operates with 1–10 employees. The company has secured $130K across one funding round from 0 investors. BioLert ceased operations in January 2021.

Business overview

BioLert Electro Medical Systems develops and manufactures medical devices for vital sign monitoring, with an initial focus on the epilepsy market. The company's core product, EpiLert, is an electro-medical device that combines smartwatch technology, a smartphone, and a patented algorithm to continuously monitor and detect seizure events. This technology aims to provide a remote monitoring solution for patients and caregivers, increasing independence and ensuring contacts are notified during severe nervous system events. BioLert operates within the Health Tech & Life Sciences sector, specifically in Medical Devices, Medical Monitors, Digital Healthcare, and Patient Remote Monitoring, serving patients and healthcare providers globally.

Company Intelligence Q&A

What is BioLert's primary product?

BioLert's primary product is EpiLert, an electro-medical device designed for the continuous remote monitoring and detection of seizure events in epilepsy patients.

When was BioLert founded?

BioLert was founded in January 2010.

What is BioLert's operational status?

BioLert is currently non-active and ceased operations in January 2021.

What technology does BioLert utilize for seizure detection?

BioLert utilizes a combination of smartwatch technology, a smartphone, and a patented algorithm to continuously monitor for and detect seizure events.

What markets does BioLert serve?

BioLert serves the global market, focusing on patients and healthcare providers within the Health Tech & Life Sciences sector.